Prollenium Medical Technologies, Inc (www.prollenium.com) to record strong year on year gains for fiscal 2008; company is ranked in PROFIT 100 amongst the nation's fastest growing companies



    AURORA, ON, June 25 /CNW/ - Ario Khoshbin, President, Prollenium Medical
Technologies, Inc., a privately held specialty pharmaceutical, reported today
that his firm will continue to record strong year on year gains in revenues
and profitability for its 2008 Fiscal Year ending June 30th. Over the past
five years, Prollenium has recorded aggregate revenue growth of more than 400%
ranking it amongst Canada's fastest growing firms.
    Prollenium's rapid growth is recognized in the 20th Annual PROFIT 100
ranking of Canada's Fastest Growing Companies published in the June Issue of
PROFIT and online at PROFIT100.COM. Prollenium Medical Technologies is the
only Canadian medical device company to make the PROFIT 100 listing in this
year's ranking.
    "The PROFIT 100 are role models for anyone who wants to expand their
business domestically or internationally," says Ian Portsmouth, editor of
PROFIT. "All entrepreneurs can take great lessons from the product
development, human resources and marketing practices of Canada's
Fastest-Growing Companies."
    Commenting on his firm's dynamic growth and development over the past
5 years, Mr Khoshbin points out that "Prollenium is engaged in a burgeoning
industry sector that is enjoying above average expansion even though the
macroeconomic picture is generally weak across the board. But, in our case, we
have every reason to be bullish on our business prospects going forward."
    Khoshbin explains that "Prollenium's recently formed Malta based
affiliate, AuraGenix BioPharma is poised to drive the company's global sales
growth with particular emphasis on major markets in Western and Central
Europe, Russia and Asia. Further, it is anticipated that during the next
couple of quarters, Prollenium will receive US FDA approval for its
REVANESSE(TM) ULTRA derma filler product line which will catapult the company
into the $200 Million US market for anti-aging and facial aesthetics products.
In addition, during the 2008/2009 Fiscal period, Prollenium will launch an
injectable for the treatment of pain associated with Osteoarthritis as well as
a complete line of physician grade skin care products. Additional pipeline
product development will involve increased expenditures on R & D as Prollenium
continues its development work on a Botulinum Type A injectable and initiates
plans to commence clinical trials for US FDA Approval on its highly successful
ReDexis(TM) derma filler."
    "Our recognition on the elite list of companies ranked in the PROFIT 100
is testimony to the success we've achieved by designing, developing and
distributing quality products that meet the highest standards of performance
and in general, our tireless pursuit of excellence in everything we do," says
Vice-President, Khasha Ighanian. "At the end of the day, this PROFIT 100
ranking also solidifies management's belief in human resources as a key driver
for growth and success within the organization."





For further information:

For further information: Ario Khoshbin, President, 1-866-353-3015 or
(905) 508-1469, ario@prollenium.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890